NCT05281042|CompletedDMC
Loading search results
Sponsor study identifier
observational
20
1 country
1
Study Start
September 13, 2021
Actual (reported)Primary Completion
November 30, 2021
Actual (reported)Study Completion
January 5, 2022
Actual (reported)The study will enroll up to 30 AMD patients diagnosed with NV-AMD in at least one eye at the time of enrollment. At the Study Visit, fluid must be present in at least one eye of the subjects. If only one eye qualifies for enrollment, that will be assigned as the study eye. If both eyes are eligible, the study eye will be assigned according to a randomization schedule. Only one eye of each subject will be enrolled in the study. All subjects will be enrolled at 1 site in the United States. Subjects must meet all inclusion and no exclusion criteria.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 5, 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 13, 2021
Actual (reported)November 30, 2021
Actual (reported)January 5, 2022
Actual (reported)March 6, 2022
Actual (reported)March 15, 2022
Actual (reported)Notal Home OCT Total Retinal Fluid (TRF) amount measured by NOA
volume \[nl\] of the TRF
5 minutes
Notal Home OCT Intra-Retinal Fluid (IRF) amount measured by NOA
volume \[nl\] of the IRF
5 minutes
Notal Home OCT Sub-Retinal Fluid (SRF) amount measured by NOA
volume \[nl\] of the SRF
5 minutes
Zeiss Cirrus OCT Total Retinal Fluid (TRF) amount measured by a human reader
volume \[nl\] of the TRF
5 minutes
Zeiss Cirrus OCT Intra-Retinal Fluid (IRF) amount measured by a human reader
volume \[nl\] of the IRF
5 minutes
Zeiss Cirrus OCT Sub-Retinal Fluid (SRF) amount measured by a human reader
Subjects who completed self-scanning on the Notal Home OCT, following a self-tutorial.
5 minuts
30 AMD patients diagnosed with NV-AMD in at least one eye at the time of enrollment. At the Study Visit, fluid must be present in at least one eye of the subjects. If only one eye qualifies for enrollment, that will be assigned as the study eye. If both eyes are eligible, the study eye will be assigned according to a randomization schedule. Only one eye of each subject will be enrolled in the study. All subjects will be enrolled at one 1 site in the United States.
Elman Retina Group
Glen Burnie, Maryland, 21061, United States
Gidi Benyamini
Notal vision Druyanov 5, Tel Aviv
20 participants (actual enrollment reported by the registry).
First Submitted
March 6, 2022
First Posted
March 15, 2022
Study Start
September 13, 2021
Actual (reported)Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
volume \[nl\] of the SRF
5 minutes
Contact the study team to confirm eligibility.
Primary Completion
November 30, 2021
Actual (reported)Study Completion
January 5, 2022
Actual (reported)Last Updated
April 5, 2022
Record last verified: 2022-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: